Anifrolumab denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for anifrolumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Anifrolumab as Duplicate Therapy

Anifrolumab (Saphnelo) is a biologic approved for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) in adults who are already on standard therapy. Cigna's duplicate-therapy denial means the plan's reviewer concluded that anifrolumab overlaps in mechanism or clinical purpose with another biologic or immunosuppressive therapy the patient is already receiving — most commonly another lupus-indicated agent.

This denial is frequently incorrect or incomplete. Anifrolumab has a distinct mechanism — it targets the type I interferon receptor — that is different from other SLE biologics. A well-documented appeal demonstrating the mechanistic and clinical distinction typically has a strong basis for reversal.

## Federal Appeal Rights

• Internal appeal: File within 180 days of the denial notice. Cigna must issue a decision within 30 days (pre-service) or 60 days (post-service).
• External review (ACA §2719): Duplicate-therapy denials qualify for binding IRO review. File for external review within approximately 4 months of the final internal denial.
• Expedited review: Available if the delay poses a serious health risk; 72-hour decision window.
• ERISA §503: Employer-plan members are entitled to full-and-fair review with access to all guidelines and criteria used in the determination.

## Documents to Gather

1. Current medication list with dates and indications — a complete, dated list of all immunosuppressive and biologic agents the patient is currently taking and the specific indication for each, so the reviewer can see that no agent serves the same mechanistic function as anifrolumab. 2. Diagnosis confirmation — rheumatology notes confirming the SLE diagnosis, disease activity documentation, and the treating physician's characterization of disease severity. 3. Prior treatment history with dates and outcomes — chart documentation of prior SLE therapies, duration, and the clinical response or reason for inadequate control. 4. Prescriber medical-necessity and differentiation letter — a signed letter from the treating rheumatologist explaining anifrolumab's distinct mechanism of action, why it is not duplicative of concurrent therapies, and the clinical rationale for adding it to the regimen. 5. Applicable guideline organization guidance — reference to the relevant rheumatology guideline organization's (e.g., ACR) recommendations for SLE management, specifically any guidance on combination or add-on biologic therapy. 6. Cigna's coverage policy — obtain Cigna's published coverage policy for anifrolumab and the specific definition of "duplicate therapy" applied; confirm whether the policy addresses mechanistic overlap versus clinical-indication overlap.

## Criteria-Mapping Structure

For each basis Cigna cited for the duplicate finding, provide a direct rebuttal: identify the other agent, state its mechanism, state anifrolumab's distinct mechanism (type I interferon receptor blockade), and show from the chart why both are simultaneously indicated. Address every cited criterion; unanswered items are treated as conceded by the reviewer.

## Practical Next Step

Request the Cigna clinical reviewer's specialty. SLE biologic appeals are significantly stronger when the internal review is conducted by a board-certified rheumatologist — if it was not, request peer-to-peer review with the treating rheumatologist and Cigna's medical director before advancing to the formal appeal.